Abstract/Summary 26
The landscape of cancer genetics in gynaecological oncology is rapidly changing. The traditional 27 family-history based approach has limitations and misses >50% mutation carrier. This is now being 28 replaced by population-based approaches. The need for changing the clinical paradigm from family-29 history based to population based BRCA1/BRCA2 testing in Ashkenazi Jews is supported by data that 30 demonstrates population-based BRCA1/BRCA2 testing does not cause psychological harm and is cost 31 effective. This article covers various genetic testing strategies for gynaecological cancers, including 32 population-based approaches, panel and direct-to-consumer testing as well the need for innovative 33 approaches to genetic counselling. Advances in genetic-testing technology and computational 34 analytics have facilitated an integrated systems medicine approach, providing increasing potential 35 for population-based genetic testing, risk stratification and cancer prevention. Genomic information 36 along-with biological/computational tools will be used to deliver predictive, preventive, personalized 37 and participatory (P4) and Precision medicine in the future. The traditional approach to genetic testing for high penetrance ovarian, breast and endometrial 48 cancer gene mutations has involved testing affected individuals from high risk families through high 49 risk cancer genetic clinics following intensive face to face genetic counselling. This family-history (FH) 50 driven approach requires individuals and general practitioner's to recognise and act on a significant 51 FH. Mutation carriers, who are unaware of their FH, who do not appreciate the risk/significance of 52 their FH, who are not proactive in seeking advice, and those who lack a strong FH (eg. from small 53 families) get excluded from this process. It is not surprising that FH based prediction models are only 54 moderately effective at predicting the presence of a BRCA1/BRCA2 mutation and have poor negative 55 likelihood ratios for predicting their absence.
[1] Their performance of these models falls further in 56 population based cohorts when comparing BRCA1/2 carrier mutation rates to those in high risk 57
families.
[2] We[2] and others [3, 4] have shown that the FH based approach misses over half the at 58 risk mutation carriers. Similar findings where significantly large proportion of identified mutation 59 carriers lack a strong FH of cancer have been reported in testing of breast cancer (BC), ovarian 60 cancer (OC) and endometrial cancer (EC) case series unselected for FH.[5-11] Furthermore, our 61 analysis of data from London genetic testing laboratories indicates that only 12% of the identifiable 62 BRCA1/BRCA2 carriers in the Ashkenazi Jewish (AJ) population have been identified over 10 years by 63 the current family history based approach. Modelling of the current rates of detection in the NHS 64 (National Health Service) indicates that it will take around 45 years to identify the carriers in the 65 London Jewish population who are detectable on the basis of a family history, and that this will still 66 miss half the people at risk. Identified BRCA1/2 and mismatch repair mutation carriers can opt for 67 risk reducing salpingo-oophorectomy (RRSO) to reduce their ovarian cancer risk; [12, 13] [17] Given the effective options available for ovarian, endometrial and breast cancer risk 72 management and prevention in these high risk women, the points above raise serious questions 73 about the adequacy of the current FH-based approach and suggest that a move towards new 74 approaches for risk prediction and case identification are justified. All of the limitations described 75 above can be overcome by a population based approach to genetic testing. 76 77
Principles of Population Testing for Genetic Cancer 78
The original 10 principles for population screening were proposed by Wilson The above published criteria do not address some key issues for population screening of cancer gene 95 mutations . It is essential that the penetrance of the gene be well established through validated 96 studies before being incorporated into a screening programme. Initial data on risk estimates for new 97 genetic discoveries may be based on small numbers with wide confidence intervals and at times do 98 not get confirmed in validation studies. Another important issue is understanding the impact of 99 genetic testing on psychological health and quality of life, particularly on a population basis. While 100 there is adequate data for high risk populations, data on this in a low-risk non-Ashkenazi Jewish 101 population are lacking. This is needed to make an appropriate assessment balancing both risks and 102 benefits of screening. It is important for prospective well designed implementation studies on 103 population-based genetic testing to be undertaken prior to implementing a screening programme. 104
Downstream management pathways should be established for at risk individuals before programme 105 implementation. As one gene may affect more than once cancer, these should also include links to 106 management options for other cancers at risk from one mutation, for e.g., colorectal cancer in 107 mismatch repair mutations/ Lynch Syndrome. A population based genetic-screening programme 108 needs to also establish and outline guidelines covering ethical and legal responsibilities such as 109 discrimination, data protection, reporting requirements, disclosure or information sharing with 110 family and health care providers, sample and data storage and ownership as well as licensing/patent 111 issues that may arise. In Table-2 as well as satisfaction with population testing amongst both men and women in the Jewish 141 population. 142
143
A key issue of concern raised by many has been that mutation penetrance with population 144 ascertainment may be less than the penetrance estimates obtained from families attending cancer 145 genetics clinics, which can range from 81-88% for BC and 21-65% for OC. [ These data indicate that breast/ovarian cancer penetrance for AJ BRCA1/BRCA2 carriers identified 155 through population testing and those without a strong FH are also 'high', though as expected these 156 estimates are a bit lower than those obtained from individuals attending cancer genetic clinics. 157 158 A health-economic evaluation is essential to balance costs and benefits in the context of setting 159 public health policy for genetic testing for BRCA1/BRCA2 mutations. Our cost-effectiveness analysis 160 suggests that population testing for BRCA1/BRCA2 mutations in AJ women >30 years reduces breast 161 and ovarian cancer incidence by 0.34% and 0.62% and saves 0.101 more Quality adjusted life-years 162 (QALYs) leading to 33 days gain in life-expectancy. We found population-based testing is extremely 163 cost-effective compared to traditional FH based approach, with a discounted incremental cos- 
Implications of the AJ Model 187
There is now good evidence to show that population testing for BRCA1/BRCA2 mutations in 188
Ashkenazi Jews fulfils the necessary principles for population screening for genetic susceptibility of 189 disease listed above (Table-2 Despite publication of guidelines and policy recognition,[49, 69] lack of funding is currently 231 preventing harmonised implementation of the population based cancer case series approach. This is 232 greatly compounded by limited awareness and knowledge of these issues amongst treating 233 clinicians, pathologists, general practitioners and the population at large. Implementation also has 234 significant implications for expansion in cancer genetics services and downstream management 235 pathways. Nevertheless, as logistics for delivery get ironed out and awareness and acceptance 236 increases, its applicability will increase and become widespread. This approach is here to stay and 237 will expand to other relevant cancers and gene mutations. 238
Panel Testing and Potential for Population based Risk Stratification 239
The genomic era has heralded a rapidly changing landscape in cancer genetics. Advances in genetic 240 testing technology with massive parallel sequencing, and big strides in computational analytics 241 enabling synthesis of complex, large volume, cross disciplinary data has facilitated an integrated 242 systems medicine approach, which in turn is transforming diagnostic, therapeutic and preventive 243 healthcare strategies. In addition to the traditional high penetrance genes (e.g. BRCA1, BRCA2 and 244 prevention needs review in the context of evaluating and implementing a population based OC risk 293 stratification strategy. We speculate that it is likely this will lie well below the current accepted 294 practice of 10% risk. Although Screening for OC has not yet been shown to reduce mortality, [ [96] have been found to be non-inferior and 319 cost-efficient compared to standard face to face counselling. There is widespread recognition that 320 successful implementation of case series testing requires a move away from the standard face-to-321 face genetic counselling approach. Informed consent and pre-test counselling needs to be delivered 322 by the non-cancer genetics professional community. Different models being explored for this 323 purpose include mainstreaming[97] and use of dedicated trained nurse specialists co-ordinated 324 through a regional genetics service.
[98] However, data comparing outcomes of these approaches 325 are lacking. Efficient, acceptable, and cost-effective ways of delivering information on genetic risk 326 will be needed for the successful implementation of any population-based testing program and this 327 area requires more research. 328 329 Specific attention also needs to be paid to pre-test counselling and post-test counselling of results in 330 the context of panel testing. This is more complicated given the large number of genes, some 331 without precise risk estimates or interventions of proven clinical benefit for identified carriers. In 332 addition uncertainty exists on how to deal with variants of uncertain significance (VUS)/ incidental 333 findings, the identification of which will increase with the number of genes tested. Results of 334 clinically significant mutations of sufficient risk need to be returned to participants and it is 335 important for the possibility of incidental findings as well as plans for disclosure/non-disclosure to be 336 discussed with participants at the outset. New approach(es) to counselling for informed consent 337 such as a 'tiered and binned' approach are being explored. Going forward, further validation studies will provide more precise risk estimates for a number of 377 the newer gene mutations. Absolute risk values derived from relative risk estimates will be made 378 available for the purpose of counselling/informed consent for genes for which they are yet 379 unavailable. We speculate that redefined thresholds for interventions like RRSO will enable 380 implementation of cost effective surgical prevention strategies for moderate penetrance OC genes. 381
Emergence of validated data in the not too distant future will lead to widespread clinical 382 implementation of panel testing for genes like RAD51C, RAD51D, BRIP1, PALB2, CHEK2, ATM, etc. in 383 women with strong FH of cancer and cancer case series. Although some have suggested that 384 population based testing for BRCA1/BRCA2 genes could now be introduced into the general non-385 Jewish population, [110] this is still premature as data on acceptability, clinical validity and cost-386 effectiveness are lacking and implementation studies have not been undertaken. However, this will 387 happen in the future once these studies are undertaken. Validated models incorporating 388 combination(s) of a range of genetic (high, moderate and low penetrant) and epidemiologic/ 389 environmental factors will become available for clinical implementation. As new risk variants are 390 discovered, the performance of risk prediction models will get refined and improve. It is important 391
for epigenomic data to also be incorporated into risk prediction models and the large data sets 392 needed to facilitate this require developing. With the declining costs of sequencing, the use of gene-393 panel testing, as well as whole-exome and whole-genome sequencing, will become more 394 widespread. Large scale prospective studies of general population based testing for a panel of cancer 395 genes/genetic variants as well as epidemiologic factors incorporated into risk prediction algorithms 396 will need to be undertaken to evaluate clinical utility, acceptability, impact on psychological health 397 and quality of life, uptake of preventive strategies, as well as cost-effectiveness, delivery pathways, 398 and long term health outcomes. An initial small pilot study for OC is proposed to commence along 399 these lines in 2016 within the PROMISE grant. interpretation will be used to deliver P4 and Precision medicine in the future. This will enable 408 introduction of individualised tailored prevention and/or treatment strategies. Integration and 409 implementation of a population screening strategy for collecting genomic and epidemiologic 410 information will be essential for the application of P4/Precision medicine approaches for cancer 411 prevention and treatment. Our current health care systems are concentrated primarily on treatment 412 of disease. They are not focused on prediction /prevention and maintaining 'wellness'. Delivery of a 413 P4/Precision medicine approach incorporating population based testing will require a big change in 414 focus. While precision medicine delivered treatment strategies for those with cancer are likely to 415 remain hospital led, approaches for prediction and prevention will require a move away from 416 hospitals and clinics to the community/high-street and/or home environment. It will involve use of 417 new and innovative information tools, resources, devices, apps and health information systems for 418 individuals to proactively participate in managing their health. It will also require the development of 419 new care pathways and relationships between participating individuals and healthcare providers. 420
Providers need to deliver predictive information as well as develop downstream management 421 pathways for delivering effective risk-reducing clinical interventions for the at-risk population and 422 monitoring long term health outcomes. Different solutions are likely to emerge for different 423 countries and commercial companies offering newer DTC models with built in safeguards. In 424 addition appropriate oversight/regulatory framework will need to be integrated into this process to 425 maximise possible impact for population benefit. Education of the public/ consumers as well as 426 general practitioners, genetic clinicians, gynaecologists, health care providers and stake holders 427 involved in management of these women remains a massive challenge which also needs addressing. 428
In January 2015, President Obama announced a precision medicine initiative with cancer as an 429 important component within the scheme.
[113] Many more such initiatives and funding streams 430 driven innovative research studies are needed to fulfil its potential. 431
432

EXECUTIVE SUMMARY 433
• The traditional family-history based approach for genetic testing has limitations and misses 434 >50% mutation carriers. It is being replaced by population-based approaches for genetic testing. 435
• Population-based BRCA1/BRCA2 testing in Ashkenazi Jews does not cause psychological harm 436 and identifies more people at risk, reduces breast and ovarian cancer incidence and is extremely 437 cost effective. This supports a change in the clinical paradigm in this population. 438
• Population-based testing of cancer case series is becoming more widespread. However, lack of 439 funding and awareness amongst clinicians is preventing harmonised implementation. Its 440 successful application requires counselling with new approaches like mainstreaming, involving 441 the non cancer genetics clinical community. 442
• The availability of high throughput technologies has led to multiplex panel testing becoming 443 available in clinics. However, a number of genes being tested in these panels lack precise cancer 444 risk estimates and uncertainty exists on how to deal with VUS and incidental findings. Pros and 445 cons need to be carefully discussed with patients by experienced and well-informed health 446 professionals. 447
• A number of newer intermediate/ moderate penetrance genes and common genetic variants 448 have recently been identified for ovarian, breast and other cancers. Development of 449 sophisticated risk models incorporating genomic and epidemiologic information coupled with 450 availability of high throughput technology for genetic testing and falling costs provides 451 opportunity for using risk stratification for the purpose of targeted primary prevention and early 452 detection. 453
• There has been widespread concern in the professional community regarding overstatement of 454 effectiveness, minimization of risks, lack of 'informed' consent, data protection issues and 455 overselling of tests by DTC companies. The appropriateness of DTC and need for proper 456 regulation and safe-guards remains a matter of ongoing debate. 457
• In the near future, emergence of validated data will lead to widespread clinical implementation 458 of panel testing for moderate penetrance genes like RAD51C, RAD51D, BRIP1, PALB2, CHEK2, 459 ATM, etc. in women with strong FH of cancer and OC/BC cancer case series. 460
• Large scale prospective studies of general population based testing for a panel of cancer 461 genes/genetic variants as well as epidemiologic factors incorporated into risk prediction 462 algorithms need to be undertaken to evaluate clinical utility, acceptability, impact on 463 psychological health/ quality of life, cost-effectiveness and long term health outcomes. 464
• Systems medicine driven approaches incorporating genomic information (genomic medicine) 465 along with appropriate biological and computational tools for data interpretation will be used to 466 deliver P4 and Precision medicine in the future. This will enable introduction of individualised 467 tailored prevention and/or treatment strategies. 
